Browse current and past press releases from The Michael J. Fox Foundation.
November 29, 2011
CHELSEA, Mass.-- Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUSTM respiratory delivery platform, announced today the award of a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). In addition, Civitas revealed today that the company's lead drug candidate for Parkinson's disease is CVT-301, an inhaled formulation of levodopa (L-dopa). The grant from MJFF will support the clinical development of CVT-3...Read More
November 14, 2011
An Evening of Comedy & Music to Benefit the Michael J. Fox Foundation for Parkinson's Research
What: A benefit evening of comedy and music to raise funds for The Michael J. Fox Foundation for Parkinson's Research. The evening featured a selection of crowd favorites lead by musical director Onree Gill with Kid Cudi and a surprise performance by Joan Jet.
The crowd was also entertained by host John Oliver featuring comedy by Mike Birbiglia and special guest Ricky Gervais. The Good Wife star, Ju...Read More
The 2011 NIKE MAG Auction Raises $4.7 Million for The Michael J. Fox Foundation for Parkinson's Research
November 11, 2011
NEW YORK—The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced that Nike's total funds raised for the Foundation, generated by the 10-day eBay auction of 1,500 pairs of limited edition 2011 NIKE MAG shoes, topped $4.7 million. The funds will go straight to the Foundation's aggressive research programs to help speed a cure for Parkinson's disease.
Not only did the release of the 2011 NIKE MAG shoes generate a remarkable sum for Parkinson's research, and resulted in the la...Read More
October 19, 2011
NEW YORK - The Michael J. Fox Foundation for Parkinson's Research today announced that it is partnering with The Kinetics Foundation to measure the impact of an innovative computer-based device, called the Objective Parkinson's Disease Measurement System (OPDM), and how it might help to better measure specific motor characteristics of Parkinson's disease (PD).
The joint venture is being added to MJFF's Parkinson's Progression Markers Initiative (PPMI), a landmark five-year clinical study aiming...Read More
Joint Statement by Six Parkinson’s Disease Organizations Regarding Proposed Label Change for Azilect
October 17, 2011
Joint Statement by Six Parkinson's Disease Organizations Regarding Proposed Label Change for Azilect
FDA Advisory Committee Meeting
This statement is prepared on behalf of the American Parkinson Disease Association, The Michael J. Fox Foundation for Parkinson's Research, the National Parkinson Foundation, the Parkinson's Action Network, the Parkinson Alliance, and the Parkinson's Disease Foundation. Together we represent a large segment of the Parkinson's disease community and, on behalf of th...Read More
MJFF Awards AFFiRiS $1.5 Million for the Clinical Development of the First Parkinson's Disease Vaccine
October 12, 2011
NEW YORK, USA AND VIENNA, AUSTRIA-The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of AFFITOPE PD01, a first-of-its-kind Parkinson's disease (PD) vaccine. AFFITOPE PD01 targets and helps remove the alpha-synuclein protein, whose clumping is the pathological hallmark of PD. Principal investigator Achim Schneeberger, MD, chief medical officer at AFFiRiS AG, will head the Phase I stud...Read More
October 03, 2011
Last week, Banner Sun Health Research Institute (BSHRI) and Mayo Clinic Arizona announced an $8 million, five-year grant from The National Institute of Neurological Disorders and Stroke (NINDS) to support a "National Brain and Tissue Resource for Parkinson's Disease and Related Disorders." The announcement comes on the heels of ongoing support from The Michael J. Fox Foundation for Parkinson's Research (MJFF).Read More
Vanderbilt-MJFF Partnership Yields Drug-Like Molecules Aimed at Improving Treatment of Parkinson's Disease
September 30, 2011
Researchers at Vanderbilt University Medical Center have achieved a milestone in the development of a potential new treatment for Parkinson's disease that may improve on some of the limitations of current therapy.
Three drug-like molecules that act on a specific glutamate receptor in the brain are ready for the next stage of preclinical testing prior to entering human trials. The molecules were developed with major support from The Michael J. Fox Foundation for Parkinson's Research (MJFF).
If ...Read More
September 27, 2011
Addex Pharmaceuticals is moving forward with a Phase IIa study evaluating the metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator, called dipraglurant (ADX48621), in reducing levodopa-induced dyskinesia in patients with Parkinson's disease (PD). The study is not impacted by Merck's recent announcement that they were pulling out of a partnership with Addex to develop positive allosteric modulators on a closely related receptor called mGluR4, said Chris Maggos, who handles bus...Read More
September 23, 2011
The Michael J. Fox Foundation (MJFF) launched the LRRK2 Cohort Consortium, a group of eight separate groups funded by MJFF to assemble and study groups of people with and without Parkinson's disease (PD) who carry mutations in the LRRK2 gene. LRRK2 is more frequently found in cases of PD than any other gene discovered to date, particularly in certain populations including Ashkenazi Jews, North African Berbers, and Asians of Chinese descent.
Comprising more than 3,000 people across 20 clinical s...Read More
Back for the Future: Nike Partners with The Michael J. Fox Foundation and Original Film Creators to Pursue a Future without Parkinson's Disease
September 09, 2011
BEAVERTON, Ore.- Nike today announced that 1500 pairs of the mythical 2011 Nike MAG shoes will be auctioned on eBay, Nikemag.eBay.com, with all net proceeds going directly to The Michael J. Fox Foundation.
"This project is exciting to me because it brings together three very passionate audiences: the Parkinson's community, sneakerheads and Back to the Future fans," said Michael J. Fox. "With their support we can accelerate our objective of finding a cure for Parkinson's."
The Nike MAG shoes or...Read More
August 31, 2011
New data suggests that LRRK2, the greatest known genetic contributor to Parkinson's disease (PD), plays a role in the disease-causing mechanism of a larger percentage of people with PD than was previously believed. The findings, from lead investigator Owen Ross, PhD, of the Mayo Clinic's Florida campus, were published online August 31 in Lancet Neurology. The study was supported with grants from The Michael J. Fox Foundation for Parkinson's Research (MJFF), which has made the validation of LRRK2...Read More
August 13, 2011
The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced a new collaboration with the Shake It Up Foundation Australia and its founder, businessman Clyde Campbell. The organizations will work to bring MJFF's landmark clinical study, the Parkinson's Progression Markers Initiative (PPMI), to Australia. The Shake It Up Foundation will raise funds for PPMI and other Parkinson's research being carried out in Australian labs. Together the two groups will capitalize on MJFF's exper...Read More
July 28, 2011
NEW YORK, NY--The Michael J. Fox Foundation (MJFF) today announced six awards totaling $2.4 million in funding under its Repositioning Drugs for PD 2011 Request For Applications (RFA). While the Foundation has supported repositioning projects before, this was the Foundation's first repositioning specific RFA.
"We are committed to bringing breakthrough Parkinson's treatments to market as quickly as possible," said Kuldip Dave, PhD, associate director of research programs at MJFF. "The developmen...Read More
July 14, 2011
THE MICHAEL J. FOX FOUNDATION DEBUTS NEW CLINICAL TRIAL MATCHING TOOL FOX TRIAL FINDER
— Web-based smart-match tool to connect volunteers with clinical trialslaunches in beta —
NEW YORK— The Michael J. Fox Foundation for Parkinson's Research today launched the beta version of Fox Trial Finder (www.foxtrialfinder.org), a Webbased solution designed to connect willing volunteers with the Parkinson's clinical trials that urgently need them."Today, as many as 80 percent of clinical trials face r...Read More
Anders Björklund, MD, PhD, Awarded Inaugural Robert A. Pritzker Prize for Leadership in Parkinson's Research by The Michael J. Fox Foundation
June 14, 2011
Karen Pritzker and Husband Michael Vlock Invest $1.5M to Recognize Critical Contributions to Parkinson's Drug Development
The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced that Anders Björklund, MD, PhD, of Lund University, Sweden, is the recipient of the first Robert A. Pritzker Prize for Leadership in Parkinson's Research. The prize honors both current cutting-edge research as well as an individual's entire body of work. Dr. Björklund was selected for his profound ...Read More
Brin Wojcicki Foundation Announces $50-Million Challenge Grant to Michael J. Fox Foundation to Spur Progress Toward Parkinson's Cure
May 31, 2011
Sergey Brin and Anne Wojcicki announced a $50-million challenge spurring existing and new donors at every level to give, or increase giving, to The Michael J. Fox Foundation for Parkinson's Research (MJFF). The Challenge is now in effect and will match all new or increased gifts to The Michael J. Fox Foundation on a one-to-one basis through year-end 2012.
The Brin Wojcicki Challenge will bolster MJFF's ongoing efforts to reshape drug development for Parkinson's disease. Founded in 2000, the F...Read More
Michael J. Fox Foundation Appoints Dr. Todd Sherer, Leader of Foundation's Scientific Strategy, as Chief Executive Officer
May 05, 2011
The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced the appointment of Todd Sherer, PhD, as chief executive officer of the organization. In his previous capacity as chief program officer, Dr. Sherer was instrumental in setting and implementing the MJFF's unique scientific strategy to intervene aggressively in closing crucial gaps that slow potential treatments' path from the laboratory to Parkinson's patients. In addition, Sherer built the organization's internal team o...Read More
April 18, 2011
Actor Ryan Reynolds, who sits on the Board of Directors of The Michael J. Fox Foundation for Parkinson's Research, is challenging his fans and the general public to get involved in helping to speed a cure for Parkinson's by "liking" the Foundation's Facebook page (facebook.com/michaeljfoxfoundation). If the Foundation reaches 100,000 Facebook fans as part of its national Parkinson's Awareness Month campaign, Reynolds will add $10,000 to his cumulative giving to the Foundation.Read More